Why Spruce Biosciences, Inc.’s (SPRB) Stock Is Down 7.07%
As of Friday, July 24, Spruce Biosciences, Inc.’s SPRB share price has dipped by 7.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Spruce Biosciences, Inc.’s (SPRB) Stock Is Up 6.62%
As of Thursday, June 18, Spruce Biosciences, Inc.’s SPRB share price has surged by 6.62%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Spruce Biosciences, Inc.’s (SPRB) Stock Is Up 5.73%
As of Wednesday, June 17, Spruce Biosciences, Inc.’s SPRB share price has surged by 5.73%, which has investors questioning if this is right time to sell.Michael Rose
Why Spruce Biosciences, Inc.’s (SPRB) Stock Is Up 8.46%
As of Thursday, June 04, Spruce Biosciences, Inc.’s SPRB share price has surged by 8.46%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Spruce Biosciences, Inc.’s (SPRB) Stock Is Up 5.77%
As of Wednesday, May 20, Spruce Biosciences, Inc.’s SPRB share price has surged by 5.77%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | SPRB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $117.9 | $252.6 | 23% |
|
| Shares Out (Mil) | 1.4 | 52.3 | 5% |
|
| Institutional Ownership | 91.1% | 92.1% | 59% |
|
| Float (Mil) | 2.4 | 40.2 | 6% |
|
| Beta | 3.20 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 52 | 455 | 29% |
|
| Price Change (52-week) |
423.9% | 52.9% | 99% |
|
| Growth | SPRB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (5.7%) | (9.9%) | 33% |
|
| EPS (5yr) | 32.8% | 16.0% | 83 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (63.0%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($5.929) | ($24.886) | $7.384 | |
| Month Ago EPS | ($6.242) | ($25.635) | $4.950 | |
| # Rev Up | 3 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($5.723) | ($24.533) | $4.300 | |
| Year/Year Chg | (33.7%) | (51.0%) | (84.2%) | |
| Financials | SPRB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($37) | ($43) | 19% |
|
| EPS (TTM) | ($38.617) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $6 | $5 | 25% |
|
| Enterprise Value (Q1) (Mil) | $89 | $180 | 20% |
|
| Valuation | SPRB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.70 | 2.56 | 45% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SPRB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (84.7%) | (49.8%) | 7% |
|
| ROE | (148.8%) | (55.5%) | 6% |
|
| Liabilities to Assets | 38.3% | 30.3% | 29% |
|
| F-Score | 3 | 3 | 19% |
|
Spruce Biosciences, Inc. did not pass any screens on 7/31/2026.
